Timepoint | Study period | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pre-treatment | Study treatment | Follow-up | ||||||||||||||||||
Enrolment | RT planning | RT start (wk 1) | RT end (wk 2) | wk 6 | wk 12 | 6 mths after RT | 9 mths after RT | 12 mths after RT | 15 mths after RT | 18 mths after RT | 21 mths after RT | 24 mths after RT | 30 mths after RT | 36 mths after RT | 42 mths after RT | 48 mths after RT | 54 mths after RT | 60 mths after RT | In case of recurrence | |
Eligibility screen | x | |||||||||||||||||||
Informed consent | x | |||||||||||||||||||
Medical history | x | x | x | x | x | x | x | x | x | x | x | x | x | |||||||
Symptoms | x | x | x | x | x | x | x | x | x | x | x | x | ||||||||
PSA level* | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | |||
MR Linac simulation | x | |||||||||||||||||||
Toxicity | x | x | x | x | x | x | x | x | x | x | x | x | ||||||||
CT pelvis | x | |||||||||||||||||||
MRI pelvis** | x | |||||||||||||||||||
EORTC QoL questionnaires | x | x | x | x | x | x | x | x | x | x | x | x | ||||||||
Blood test | x |